Fulcrum Therapeutics (FULC) vs Galectin Therapeutics (GALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Galectin Therapeutics (GALT) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 49.7% versus a loss of 67.3%. Over five years, GALT leads with a +4.7% price change compared with -75.5% for FULC. Fulcrum Therapeutics is the larger company by market cap ($281.8 million vs $271.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FULC | GALT |
|---|---|---|
| Share price | $3.69 | $2.69 |
| Market cap | $281.85M | $271.35M |
| 1-day change | -0.54% | -4.27% |
| YTD return | -67.37% | -35.34% |
| 1-year return | -67.32% | -49.72% |
| 5-year return | -75.50% | +4.67% |
| EPS (TTM) | $-1.04 | $-0.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-74.88M | $-30.84M |
| 52-week high | $15.74 | $7.13 |
| 52-week low | $2.83 | $2.03 |
| Distance from 52-week high | -76.56% | -62.27% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -0.54% | +308.92% |
| Average volume | 1.37M | 252.31K |
| Shares outstanding | 76.38M | 100.88M |
| Employees | 55 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GALT has outperformed FULC by 17.6 percentage points over the past year.
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
FULC vs GALT FAQ
Which is bigger, Fulcrum Therapeutics or Galectin Therapeutics?
Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $281.85M compared with $271.35M for Galectin Therapeutics (GALT).
Which stock has performed better over the past year, FULC or GALT?
GALT returned -49.72% over the past 12 months, compared with -67.32% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Fulcrum Therapeutics and Galectin Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.